Using TNF as predictive marker and TGFB1 and EDN1 as monitoring markers might be a valuable strategy finding the subset of diabetic nephropathy patients benefitting the most from tacrolimus treatment. The gene discussed is TGFB1; the disease is diabetic kidney disease.